BRPI1009381A2 - compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica - Google Patents

compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica

Info

Publication number: BRPI1009381A2
Authority: BR; Brazil
Prior art keywords: compounds; pharmaceutical composition; trap1; subject; need
Prior art date: 2009-03-23

Application number

BRPI1009381A

Other languages

English (en)

Inventor

Abraham Thomas

Indranil Mukhopadhyay

Nayan Taterao Waghmare

Neelima Khairatkar-Joshi

Sanjay Margal

Sukeerthi Kumar

Original Assignee

Glenmark Pharmaceuticals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-23

Filing date

2010-03-23

Publication date

2016-06-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42780205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1009381(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-03-23 Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa

2016-06-21 Publication of BRPI1009381A2 publication Critical patent/BRPI1009381A2/pt

2020-04-14 Publication of BRPI1009381B1 publication Critical patent/BRPI1009381B1/pt

2021-05-25 Publication of BRPI1009381B8 publication Critical patent/BRPI1009381B8/pt

Links

150000001875 compounds Chemical class 0.000 title 2
239000008194 pharmaceutical composition Substances 0.000 title 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI1009381A 2009-03-23 2010-03-23 compostos, composição farmacêutica e uso de compostos e de composição farmacêutica BRPI1009381B8 (pt)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
IN665MU2009		2009-03-23
US17135509P	2009-04-21	2009-04-21
IN2213MU2009		2009-09-23
US25194409P	2009-10-15	2009-10-15
IN2906MU2009		2009-12-16
US29447010P	2010-01-12	2010-01-12
PCT/IB2010/000930 WO2010109334A2 (en)	2009-03-23	2010-03-23	Thienopyrimidinedione derivatives as trpa1 modulators

Publications (3)

Publication Number	Publication Date
BRPI1009381A2 true BRPI1009381A2 (pt)	2016-06-21
BRPI1009381B1 BRPI1009381B1 (pt)	2020-04-14
BRPI1009381B8 BRPI1009381B8 (pt)	2021-05-25

Family

ID=42780205

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI1013705A BRPI1013705A2 (pt)	2009-03-23	2010-03-22	compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI1009381A BRPI1009381B8 (pt)	2009-03-23	2010-03-23	compostos, composição farmacêutica e uso de compostos e de composição farmacêutica

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BRPI1013705A BRPI1013705A2 (pt)	2009-03-23	2010-03-22	compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica

Country Status (22)

Country	Link
US (4)	US20120178766A1 (pt)
EP (3)	EP2411395B1 (pt)
JP (2)	JP2012521406A (pt)
KR (2)	KR20110128898A (pt)
CN (3)	CN102361874A (pt)
AP (1)	AP2948A (pt)
AU (2)	AU2010227225A1 (pt)
BR (2)	BRPI1013705A2 (pt)
CA (2)	CA2756535A1 (pt)
DK (3)	DK2411395T3 (pt)
EA (2)	EA201190138A1 (pt)
ES (3)	ES2424341T3 (pt)
HU (1)	HUE024538T2 (pt)
IL (2)	IL215177A (pt)
MX (1)	MX2011009822A (pt)
PE (2)	PE20120834A1 (pt)
PL (3)	PL2411395T3 (pt)
PT (3)	PT2411395E (pt)
SG (4)	SG184767A1 (pt)
SI (3)	SI2411395T1 (pt)
WO (2)	WO2010109329A1 (pt)
ZA (2)	ZA201107650B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI1013559A2 (pt)	2009-03-23	2016-04-12	Glenmark Pharmaceuticals Sa	compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos
EP2411395B1 (en)	2009-03-23	2013-05-29	Glenmark Pharmaceuticals S.A.	Furopyrimidinedione derivatives as trpa1 modulators
AR084294A1 (es) *	2010-12-20	2013-05-08	Glenmark Pharmaceuticals Sa	Compuestos de 2-amino-4-ariltiazol, metodos para su sintesis y uso como antagonista de trpa1
EP2520566A1 (en)	2011-05-06	2012-11-07	Orion Corporation	New Pharmaceutical Compounds
CA2836856A1 (en) *	2011-06-13	2012-12-20	Glenmark Pharmaceuticals, S.A.	Treatment of respiratory disorders using trpa1 antagonists
WO2012176105A1 (en)	2011-06-22	2012-12-27	Glenmark Pharmaceuticals Sa	Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
BR112013031820A2 (pt) *	2011-06-22	2016-12-13	Glenmark Pharmaceutical S A	composições farmacêuticas, incluindo para administração oral e por inalação, usos de quantidade sinergicamente eficaz de antagonista trpa1 e métodos para tratar distúrbios respiratórios e para melhorar a função pulmonar
JP2014521634A (ja) *	2011-07-25	2014-08-28	グレンマークファーマシューティカルズ，エセ．アー．	Ｔｒｐａ１アンタゴニスト及びステロイドを含む医薬組成物
EP2787991A1 (en)	2011-12-05	2014-10-15	Glenmark Pharmaceuticals S.A.	Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
IN2014MN02467A (pt) *	2012-06-08	2015-07-10	Glenmark Pharmaceuticals Sa
CA2884922C (en)	2012-10-01	2020-11-10	Orion Corporation	N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists
CA2912578A1 (en)	2013-06-20	2014-12-24	Glenmark Pharmaceuticals S.A.	Nanoparticulate formulation comprising a trpa1 antagonist
CN105813638A (zh) *	2013-10-15	2016-07-27	格兰马克药品股份有限公司	包含trpa1拮抗剂和镇痛剂的药物组合物
EP3180340B1 (en) *	2014-08-11	2018-10-10	Hydra Biosciences, Inc.	Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2016023831A1 (en) *	2014-08-11	2016-02-18	Hydra Biosciences, Inc.	Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016023825A1 (en) *	2014-08-11	2016-02-18	Hydra Biosciences, Inc.	Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180345B1 (en) *	2014-08-11	2018-10-10	Hydra Biosciences, Inc.	Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
WO2016028325A1 (en)	2014-08-22	2016-02-25	Duke University	Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016042501A1 (en)	2014-09-16	2016-03-24	Glenmark Pharmaceuticals S.A.	Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en)	2015-01-09	2022-01-25	Duke University	TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017060488A1 (en)	2015-10-09	2017-04-13	Almirall, S.A.	New trpa1 antagonists
WO2017064068A1 (en)	2015-10-14	2017-04-20	Almirall, S.A.	New trpa1 antagonists
EP3439656A4 (en) *	2016-04-07	2020-03-11	Duke University	DOUBLE SMALL MOLECULE INHIBITORS OF TRPV4 AND TRPA1 FOR DISINFECTION AND ANESTHESIA
WO2018162607A1 (en) *	2017-03-07	2018-09-13	F. Hoffmann-La Roche Ag	Oxadiazole transient receptor potential channel inhibitors
CN109422749B (zh) *	2017-08-21	2023-01-24	重庆医药工业研究院有限责任公司	一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
CN114555601B (zh)	2019-10-15	2024-04-02	勃林格殷格翰国际有限公司	新颖的四唑类
CA3193607A1 (en) *	2020-10-14	2022-04-21	Boehringer Ingelheim International Gmbh	Tetrazole derivatives as trpa1 inhibitors
US11661427B2 (en) *	2020-10-14	2023-05-30	Boehringer Ingelheim International Gmbh	Tetrazole derivatives as TRPA1 inhibitors
WO2022179469A1 (zh) *	2021-02-23	2022-09-01	南京明德新药研发有限公司	噻吩并嘧啶二酮类化合物及其应用
JP7565457B2 (ja)	2021-04-14	2024-10-10	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ＴＲＰＡ１阻害剤としての３Ｈ，４Ｈ－チエノ－［２，３－ｄ］ピリミジン－４－オン誘導体
CN114656480B (zh) *	2022-04-27	2024-01-26	成都施贝康生物医药科技有限公司	噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114671875A (zh) *	2022-04-27	2022-06-28	成都施贝康生物医药科技有限公司	新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
WO2025264860A2 (en)	2024-06-18	2025-12-26	Yale University	Methods of treating post-covid airway disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2248231A1 (de)	1972-10-02	1974-04-11	Basf Ag	3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
SE9702001D0 (sv) *	1997-05-28	1997-05-28	Astra Pharma Prod	Novel compounds
PT1107973E (pt) *	1998-08-28	2004-03-31	Astrazeneca Ab	Novas tieno¬2,3-d\| pirimidinodionas processo para a sua preparacao e sua utilizacao em terapia
ES2193839B1 (es) *	2001-06-22	2005-02-16	Almirall Prodesfarma, S.A.	Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
GB0118479D0 (en) *	2001-07-28	2001-09-19	Astrazeneca Ab	Novel compounds
AU2003253165A1 (en) *	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Pyrimidine fused bicyclic metalloproteinase inhibitors
JP2006514684A (ja) *	2002-10-30	2006-05-11	バーテックス　ファーマシューティカルズ　インコーポレイテッド	Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物
US6890923B2 (en) *	2002-12-16	2005-05-10	Astrazeneca Ab	Compounds
US7465581B2 (en)	2002-12-18	2008-12-16	The Scripps Research Institute	ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons
SE0300119D0 (sv) *	2003-01-17	2003-01-17	Astrazeneca Ab	Novel compounds
EP1657238A4 (en)	2003-08-22	2008-12-03	Takeda Pharmaceutical	CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE
EP1713815A4 (en) *	2004-02-11	2009-03-11	Smithkline Beecham Corp	PTH AGONISTS
US20070196866A1 (en)	2004-03-13	2007-08-23	Irm Llc	Modulators of ion channel trpa1
EP1847541A4 (en) *	2005-02-03	2009-12-30	Takeda Pharmaceutical	CONDENSED PYRIMIDINE DERIVATIVE AND USE THEREOF
AU2006278592A1 (en) *	2005-08-04	2007-02-15	Apogee Biotechnology Corporation	Sphingosine kinase inhibitors and methods of their use
ES2344751T3 (es) *	2005-11-08	2010-09-06	N.V. Organon	Derivados de 2-(benzoimidazol-1-il)-n-(4-feniltiazol-2-il)acetamida utiles en el tratamiento de trastornos relacionados con trpv1.
WO2007054480A1 (en) *	2005-11-08	2007-05-18	N.V. Organon	2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
US20070105920A1 (en) *	2005-11-08	2007-05-10	Akzo Nobel N.V.	2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
TW201900217A (zh)	2005-12-22	2019-01-01	美商海卓勒生物科學公司	用於調節ｔｒｐａ１功能之化合物
TW200800997A (en)	2006-03-22	2008-01-01	Astrazeneca Ab	Chemical compounds
CL2008000252A1 (es) *	2007-01-29	2008-03-14	Xenon Pharmaceuticals Inc	Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
SI3184527T1 (sl) *	2007-06-22	2020-03-31	Eli Lilly And Company	Spojine 2,6-diokso,-2,3-dihidro-1H-purina uporabne za zdravljenje stanj povezanih z aktivnostjo TRPA1 kanala
CN101711413B (zh) *	2007-06-25	2013-09-04	桑迪士克科技股份有限公司	具有位于存储元件之间的可单独控制的屏蔽板的非易失性存储装置
WO2010004390A1 (en)	2008-06-17	2010-01-14	Glenmark Pharmaceuticals, S.A.	Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en)	2008-06-27	2009-12-30	Hydra Biosciences, Inc.	Methods and compositions for treating disorders
UA103918C2 (en)	2009-03-02	2013-12-10	Айерем Элелси	N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US8623880B2 (en)	2009-03-23	2014-01-07	Glenmark Pharmaceuticals S.A.	Fused pyrimidine-dione derivatives as TRPA1 modulators
EP2411395B1 (en)	2009-03-23	2013-05-29	Glenmark Pharmaceuticals S.A.	Furopyrimidinedione derivatives as trpa1 modulators
DK2411397T3 (da)	2009-03-23	2013-08-05	Glenmark Pharmaceuticals Sa	Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
AR076332A1 (es)	2009-04-21	2011-06-01	Boehringer Ingelheim Int	Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
US8440710B2 (en)	2009-10-15	2013-05-14	Hoffmann-La Roche Inc.	HSL inhibitors useful in the treatment of diabetes
EA201290147A1 (ru)	2009-10-15	2012-11-30	Пфайзер Инк.	Пирроло[2,3-d]пиримидиновые соединения
AR078522A1 (es)	2009-10-15	2011-11-16	Lilly Co Eli	Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CN102812022B (zh)	2010-01-12	2016-02-03	Ab科学有限公司	噻唑和噁唑激酶抑制剂
BR112012004154A2 (pt)	2010-07-13	2017-05-30	Novartis Ag	"derivados de oxazina e seu uso no tratamento de distúrbios neurológicos"

2010
- 2010-03-22 EP EP10716050.9A patent/EP2411395B1/en not_active Not-in-force
- 2010-03-22 ES ES10716050T patent/ES2424341T3/es active Active
- 2010-03-22 US US13/257,280 patent/US20120178766A1/en not_active Abandoned
- 2010-03-22 WO PCT/IB2010/000840 patent/WO2010109329A1/en not_active Ceased
- 2010-03-22 CN CN2010800134701A patent/CN102361874A/zh active Pending
- 2010-03-22 AU AU2010227225A patent/AU2010227225A1/en not_active Abandoned
- 2010-03-22 EA EA201190138A patent/EA201190138A1/ru unknown
- 2010-03-22 DK DK10716050.9T patent/DK2411395T3/da active
- 2010-03-22 SG SG2012069472A patent/SG184767A1/en unknown
- 2010-03-22 PE PE2011001704A patent/PE20120834A1/es not_active Application Discontinuation
- 2010-03-22 BR BRPI1013705A patent/BRPI1013705A2/pt not_active IP Right Cessation
- 2010-03-22 JP JP2012501412A patent/JP2012521406A/ja active Pending
- 2010-03-22 SI SI201030233T patent/SI2411395T1/sl unknown
- 2010-03-22 PT PT107160509T patent/PT2411395E/pt unknown
- 2010-03-22 KR KR1020117022604A patent/KR20110128898A/ko not_active Withdrawn
- 2010-03-22 PL PL10716050T patent/PL2411395T3/pl unknown
- 2010-03-22 CA CA2756535A patent/CA2756535A1/en not_active Abandoned
- 2010-03-22 SG SG2011066446A patent/SG174398A1/en unknown
- 2010-03-23 SG SG2012069530A patent/SG184769A1/en unknown
- 2010-03-23 WO PCT/IB2010/000930 patent/WO2010109334A2/en not_active Ceased
- 2010-03-23 AP AP2011005889A patent/AP2948A/xx active
- 2010-03-23 HU HUE13002731A patent/HUE024538T2/hu unknown
- 2010-03-23 EA EA201190139A patent/EA022029B1/ru unknown
- 2010-03-23 ES ES13002731.1T patent/ES2532386T3/es active Active
- 2010-03-23 CA CA2756536A patent/CA2756536C/en active Active
- 2010-03-23 DK DK13002731T patent/DK2634191T3/en active
- 2010-03-23 JP JP2012501414A patent/JP5612070B2/ja not_active Expired - Fee Related
- 2010-03-23 SI SI201030891T patent/SI2634191T1/sl unknown
- 2010-03-23 BR BRPI1009381A patent/BRPI1009381B8/pt active IP Right Grant
- 2010-03-23 KR KR1020117022603A patent/KR101524337B1/ko not_active Expired - Fee Related
- 2010-03-23 PT PT13002731T patent/PT2634191E/pt unknown
- 2010-03-23 EP EP13002731.1A patent/EP2634191B1/en active Active
- 2010-03-23 PT PT107517120T patent/PT2411396E/pt unknown
- 2010-03-23 CN CN201310628814.5A patent/CN103755720B/zh not_active Expired - Fee Related
- 2010-03-23 PE PE2011001705A patent/PE20120775A1/es active IP Right Grant
- 2010-03-23 US US12/936,451 patent/US8507503B2/en not_active Expired - Fee Related
- 2010-03-23 PL PL13002731T patent/PL2634191T3/pl unknown
- 2010-03-23 EP EP10751712.0A patent/EP2411396B1/en active Active
- 2010-03-23 MX MX2011009822A patent/MX2011009822A/es unknown
- 2010-03-23 ES ES10751712T patent/ES2424342T3/es active Active
- 2010-03-23 PL PL10751712T patent/PL2411396T3/pl unknown
- 2010-03-23 DK DK10751712.0T patent/DK2411396T3/da active
- 2010-03-23 AU AU2010227230A patent/AU2010227230B2/en not_active Ceased
- 2010-03-23 CN CN201080013463.1A patent/CN102361877B/zh not_active Expired - Fee Related
- 2010-03-23 SG SG2011066503A patent/SG174404A1/en unknown
- 2010-03-23 SI SI201030231T patent/SI2411396T1/sl unknown
2011
- 2011-09-15 IL IL215177A patent/IL215177A/en not_active IP Right Cessation
- 2011-09-15 IL IL215175A patent/IL215175A/en active IP Right Grant
- 2011-10-19 ZA ZA2011/07650A patent/ZA201107650B/en unknown
- 2011-10-19 ZA ZA2011/07649A patent/ZA201107649B/en unknown
2013
- 2013-06-25 US US13/925,975 patent/US8987278B2/en active Active
2015
- 2015-02-12 US US14/620,721 patent/US9474758B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK2634191T3 (en)	2015-03-23
EP2634191B1 (en)	2014-12-24
HK1166073A1 (en)	2012-10-19
IL215177A0 (en)	2011-12-29
ES2424341T3 (es)	2013-10-01
ZA201107650B (en)	2012-07-25
WO2010109329A1 (en)	2010-09-30
PE20120775A1 (es)	2012-06-27
DK2411396T3 (da)	2013-08-05
PL2411396T3 (pl)	2013-10-31
IL215177A (en)	2014-01-30
IL215175A (en)	2014-01-30
AU2010227230A2 (en)	2011-10-27
AP2011005889A0 (en)	2011-10-31
US20130289054A1 (en)	2013-10-31
IL215175A0 (en)	2011-12-29
SG174398A1 (en)	2011-10-28
AU2010227225A1 (en)	2011-09-15
CN102361874A (zh)	2012-02-22
SI2411396T1 (sl)	2013-07-31
CA2756536A1 (en)	2010-09-30
CN103755720A (zh)	2014-04-30
US20120178766A1 (en)	2012-07-12
SG184767A1 (en)	2012-10-30
US20120295924A1 (en)	2012-11-22
PL2634191T3 (pl)	2015-06-30
DK2411395T3 (da)	2013-08-05
SG184769A1 (en)	2012-10-30
SI2634191T1 (sl)	2015-04-30
AU2010227225A2 (en)	2011-10-06
BRPI1013705A2 (pt)	2016-04-05
JP2012521406A (ja)	2012-09-13
KR20120004422A (ko)	2012-01-12
HK1166074A1 (en)	2012-10-19
PT2411396E (pt)	2013-06-06
EA201190138A1 (ru)	2013-05-30
BRPI1009381B1 (pt)	2020-04-14
CA2756535A1 (en)	2010-09-30
US20150150876A1 (en)	2015-06-04
PT2411395E (pt)	2013-06-06
WO2010109334A2 (en)	2010-09-30
SI2411395T1 (sl)	2013-07-31
PT2634191E (pt)	2015-03-04
ES2532386T3 (es)	2015-03-26
KR20110128898A (ko)	2011-11-30
CN103755720B (zh)	2016-07-06
US9474758B2 (en)	2016-10-25
WO2010109334A3 (en)	2010-11-25
BRPI1009381B8 (pt)	2021-05-25
CA2756536C (en)	2015-10-06
EP2411395B1 (en)	2013-05-29
EP2634191A1 (en)	2013-09-04
MX2011009822A (es)	2012-01-25
EA022029B1 (ru)	2015-10-30
PE20120834A1 (es)	2012-07-25
JP5612070B2 (ja)	2014-10-22
HUE024538T2 (hu)	2016-01-28
US8987278B2 (en)	2015-03-24
ZA201107649B (en)	2012-07-25
AP2948A (en)	2014-07-31
AU2010227230A1 (en)	2011-09-22
EP2411395A1 (en)	2012-02-01
EP2411396B1 (en)	2013-05-29
JP2012521407A (ja)	2012-09-13
SG174404A1 (en)	2011-10-28
EA201190139A1 (ru)	2012-03-30
CN102361877A (zh)	2012-02-22
KR101524337B1 (ko)	2015-05-29
PL2411395T3 (pl)	2013-10-31
CN102361877B (zh)	2014-05-07
US8507503B2 (en)	2013-08-13
ES2424342T3 (es)	2013-10-01
EP2411396A2 (en)	2012-02-01
AU2010227230B2 (en)	2015-11-26

Legal Events

Date	Code	Title	Description
2016-06-28	B15I	Others concerning applications: loss of priority
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-15	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-01-22	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2020-02-11	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-04-14	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/04/2020, OBSERVADAS AS CONDICOES LEGAIS.
2020-06-02	B25D	Requested change of name of applicant approved	Owner name: ICHNOS SCIENCES SA (CH)
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
BRPI1009381A2 (pt)	2016-06-21	compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BR112015003332A2 (pt)	2017-09-26	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt)	2018-04-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI0816097A2 (pt)	2016-11-01	composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
CO6791606A2 (es)	2013-11-14	Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas
BR112013020352A2 (pt)	2017-08-08	composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo
BR112013019083A2 (pt)	2017-04-04	combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
BR112012015540A2 (pt)	2019-09-24	composto, uso de composto, método para tratar um individuo, método de inibir janus quinases em um individuo, composição farmacêutica e combinação de produto
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BR112012018947A8 (pt)	2017-12-19	composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BRPI0811542A2 (pt)	2014-11-18	Composto, formulação farmacêutica, uso de um composto, e, métodos para inibir a atividade de bace, e para tratar ou prevenir uma patologia relacionada com abeta em um mamífero composto, formulação farmacêutica, uso de um composto, e, métodos para inibir a atividade de bace, e, para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BR112014010206A2 (pt)	2017-05-16	composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BRPI0919231A2 (pt)	2018-01-09	agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
PT2426148E (pt)	2015-10-26	Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BR112012018951A2 (pt)	2017-06-27	composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BRPI0910963A2 (pt)	2016-01-05	composição imunogênica, método para tratar ou prevenir doença pneumocócica, e , uso de uma composição imunogênica
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BR112012008854A2 (pt)	2015-09-22	combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0917189A2 (pt)	2015-11-10	dispositivo para uso em tratamento cirúrgico de tórax em funil e método de tratamento.
BRPI0922233A2 (pt)	2018-05-29	compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0908503A2 (pt)	2015-09-29	partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BR112012022879A2 (pt)	2016-06-14	composto, composição farmacêutica, uso do composto e método de tratamento